SND006 is an innovative bispecific antibody independently developed by Sinorda Biomedicine, for which the company holds worldwide rights. We are pleased to accelerate the development and manufacturing of Sinorda Biomedicine’s innovative bispecific antibody SND006 through our integrated technology platforms and comprehensive capabilities. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing. WuXi Biologics regards sustainability as the cornerstone of long-term business growth. WuXi Biologics ContactsBusinessinfo@wuxibiologics.comMediaPR@wuxibiologics.comSource